These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33635530)

  • 1. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
    Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
    Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
    Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
    Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
    Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
    Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
    Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice.
    Shimizu K; Nakajima Y; Takami E; Nakano H; Nogami K
    Thromb Haemost; 2024 May; ():. PubMed ID: 38677278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.